GLYCOPYRRONIUM TOSYLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GLYCOPYRRONIUM TOSYLATE (GLYCOPYRRONIUM TOSYLATE).
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
| Metabolism | Primarily excreted unchanged in urine and bile; minimal hepatic metabolism (not significantly via CYP450 enzymes). |
| Excretion | Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion. |
| Half-life | Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity. |
| Protein binding | ~40% bound to albumin; minimal binding to α1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.4–0.6 L/kg (approximately 30 L in 70 kg adult); indicates distribution primarily into extracellular fluid and highly perfused tissues; limited CNS penetration due to quaternary ammonium structure. |
| Bioavailability | Oral: <5% (extensive first-pass metabolism); Inhalation: 10–15% (systemic absorption from lungs); IM: 90–100%. |
| Onset of Action | IV: 1 minute; IM: 15–30 minutes; Inhalation: 30–60 minutes (bronchodilation); Oral: not clinically relevant (rapidly degraded in GI tract). |
| Duration of Action | Duration: 6–8 hours for anticholinergic effects (e.g., reduced secretions, bronchodilation); shorter for cardiac effects (2–4 hours). Note: In anesthesia, vagolytic effects last 2–3 hours. |
| Molecular Weight | 443.5 |
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
| Dosage form | CLOTH |
| Renal impairment | eGFR 30-59 mL/min: administer 50% of normal dose; eGFR <30 mL/min: administer 25% of normal dose. |
| Liver impairment | No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Children 2-12 years: 0.04-0.1 mg/kg orally 3-4 times daily (maximum 8 mg/day). |
| Geriatric use | Elderly patients: start at low end of dosing range (1 mg twice daily) due to increased anticholinergic sensitivity. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at doses up to 25 mg/kg/day. Use only if clearly needed. |
| 2nd trimester | No known risk; consider anticholinergic effects on fetus (e.g., tachycardia, meconium ileus). Use with caution. |
| 3rd trimester | Potential for neonatal anticholinergic effects (e.g., ileus, respiratory depression). Avoid near term unless necessary. |
Clinical note
Comprehensive clinical and safety monograph for GLYCOPYRRONIUM TOSYLATE (GLYCOPYRRONIUM TOSYLATE).
| Placental transfer | Crosses placenta in animals; human data limited but expected due to low molecular weight and lipid solubility. |
| Breastfeeding | Excretion into breast milk is unknown; due to low oral bioavailability and short half-life, unlikely to affect infant. Monitor for anticholinergic effects (e.g., irritability, feeding problems). |
■ FDA Black Box Warning
Not applicable; no FDA black box warning for glycopyrronium tosylate.
| Serious Effects |
Hypersensitivity to glycopyrronium or any componentGlaucoma (narrow-angle)Obstructive uropathy (e.g., prostatic hypertrophy)Gastrointestinal obstruction (e.g., pyloric stenosis)Myasthenia gravisTachyarrhythmiasToxic megacolon
| Precautions | Not recommended for use in patients with glaucoma, urinary retention, or gastrointestinal obstruction due to anticholinergic effects, Use with caution in patients with autonomic neuropathy, hyperthyroidism, coronary artery disease, congestive heart failure, or hiatal hernia associated with reflux esophagitis, May cause heat prostration in high environmental temperatures due to decreased sweating, May cause drowsiness or blurred vision; caution patients about operating machinery |
| Food/Dietary | No significant food interactions reported. Avoid alcohol consumption as it may worsen anticholinergic side effects like dizziness or dry mouth. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Glycopyrronium tosylate is a quaternary ammonium anticholinergic agent. Teratogenic risk data in humans are limited. Animal studies have not shown teratogenic effects at clinically relevant doses. In the first trimester, the drug is not recommended unless clearly necessary. During the second and third trimesters, uterine blood flow should be considered due to potential anticholinergic effects, though no specific fetal malformations are documented. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and signs of anticholinergic toxicity (e.g., constipation, urinary retention, blurred vision). Fetal monitoring should include heart rate assessment, especially during prolonged use in third trimester due to potential uterine relaxation effects. No specific additional monitoring required. |
| Fertility Effects | No significant effects on fertility have been reported in animal studies. Human data are absent. Potential anticholinergic effects may theoretically impact reproductive function but are unlikely at standard doses. |
| Clinical Pearls | Glycopyrronium tosylate is a quaternary ammonium anticholinergic with minimal CNS penetration due to its permanent positive charge, making it preferred over atropine for reducing secretions without central anticholinergic effects. It is used for chronic obstructive pulmonary disease (COPD) maintenance therapy and to reduce drooling in children with cerebral palsy. Onset of bronchodilation occurs within 5 minutes, peaking at 30 minutes. Monitor for anticholinergic side effects including dry mouth, constipation, and urinary retention. Caution in patients with narrow-angle glaucoma, myasthenia gravis, or prostatic hyperplasia. |
| Patient Advice | Use exactly as prescribed; do not exceed the recommended dose. · If using an inhaler, shake well before each use and prime if required. · Avoid contact with eyes; may cause temporary blurred vision. · Report symptoms such as difficulty urinating, eye pain, or severe constipation. · May cause dry mouth; use sugarless gum or candy to alleviate. · Do not stop taking suddenly without consulting your healthcare provider. · Store at room temperature away from moisture and heat. |